HYALURONIDASE
1500 IU Enzymatic Precision Mandatory Physician Safety Protocol
- Rapid & Effective Filler Dissolution
- Enzymatic Precision
- Enhanced Patient Safety
NEUVAGE Hyaluronidase is a highly purified enzyme formulated to safely dissolve hyaluronic acid fillers and restore normal tissue function.
Rapid Filler Dissolution
Restores Normal Tissue Function
Reduces Complication Risk
Precision Enzymatic Action
Physician Safety Essential
Clinical Problem
Any patient presenting blanching, pain, or colour change following HA filler injection requires immediate intervention. Delayed treatment risks permanent vascular compromise.
Hyaluronidase is the non-negotiable first-response protocol for all Neuvage-administering physicians.
Clinical Photography
Treatment Areas
Target Patient
Post-HA filler vascular complications — critical priority
Filler dissatisfaction — overcorrection or asymmetry
Tyndall effect / palpable nodule following HA
Filler migration into unintended anatomical planes
High-risk anatomy patients pre-treatment
All Neuvage VASTO-administering physicians
PRODUCT BENEFITS
Rapid filler dissolution
Restores normal tissue function
Reduces complication risk
Precision enzymatic action
Essential for physician safety
Product Benefits
HA degradation
- at 60 minutes
Enzymatic activity peaks within 15–20 minutes — fast enough to prevent vascular compromise.
PRECISION CORRECTION
Targeted enzymatic dissolution without disrupting surrounding tissue architecture.
Hypersensitivity Rate
Across decades of clinical use.
The gold standard safety anchor for HA-based procedures.
NATURAL CLEARANCE
HA fragments cleared through normal lymphatic and metabolic pathways.
No residual enzymatic activity.
Product Composition
Ingredient
Function
Hyaluronidase (lyophilised)
1500 IU per vial • Powder for reconstitution
Specific Activity
1800–2300 IU/mg • Pharmaceutical-grade precision
Stabiliser
Mannitol-stabilised formulation
pH
5.50–6.50 • Optimal physiological enzymatic activity
Reconstitution
Add 10mL NaCl 0.9% → 150 IU/mL working solution
Clinical Performance
Mechanism of Action
Neuvage™ Hyaluronidase works through a precise enzymatic mechanism to effectively dissolve hyaluronic acid fillers and restore normal tissue function safely.
1. Substrate Recognition
2. Catalytic Hydrolysis
3. Mannitol Antioxidant Support
4. Viscosity Reduction
5. Natural Clearance
Clinical Performance
Hyaluronidase
Precisely Measured.
NEUVAGE Hyaluronidase is a highly purified enzyme formulated to safely dissolve hyaluronic acid fillers and restore normal tissue function.
IU/mg
Enzymatic Activity
HA Degradation
at 60 min
Diffusion vs
Unheated ECM
Hypersensitivity
Rate
15 - 20
Minutes to
Peak Activity
IU per Vial
Clinical Data over time
HA Degradation Over Time
(% Degradation at 60 min)
HA degradation (60 minutes)
Time to Peak Activity
(Minutes)
15-20 min
Time to peak activity
Diffusion vs Unheated ECM
(Fold Increase)
Faster diffusion vs unheated ECM
More Than Numbers. Real skin Benefits.
Rapid Filler Dissolution
Effectively breaks down hyaluronic acid fillers for immediate relief.
Restores Normal Tissue Function
Helps restore natural tissue dynamics and circulation.
Reduces Complication Risk
Lower risk of vascular compromise and adverse events.
Precision Enzymatic Action
Targets hyaluronic acid specifically without damaging tissue.
Physician Safety Essential
High purity, low immunogenicity for maximum safety.
Visible Rejuvenation
Supports natural healing and improves overall skin appearance.
Clinical Results
Vascular Compromise
200–600 IU
Glabella / forehead — critical zone
Nasolabial / Labial
150–300 IU
Repeat PRN — angular / labial arteries
Nasal Tip / Temporal
300–500 IU
High-risk anatomy zones
Cheeks / Midface
50–100 IU
Glabella · Forehead · Nasolabial Field · Nasal Tip · Temporal · Cheeks · Midface · Periorbital
Treatment Areas
Glabella · Forehead · Nasolabial Field · Nasal Tip · Temporal · Cheeks · Midface · Periorbital
Frequently Asked Questions
Scientific References
- Anatomical risk classification and dosing guidelines · consensus aesthetic medicine literature
- EU GMP lyophilised vial manufacturing · sterility and potency per lot · mannitol stability validation
- Enzymatic activity validation · 2,050 IU/mg specification · pharmaceutical-grade quality control
Duration
All clinical data referenced from published peer-reviewed sources. For professional use by qualified healthcare providers only. Not for patient self-diagnosis or treatment.
